11 Red Days In A Row: BridgeBio Pharma Stock Is Down 10%
A persistent daily decline in this biotech stock is forcing a look at its underlying numbers, which tell a divided story.
BridgeBio Pharma (BBIO) has seen its market value shrink by about $1.7 billion during a slide that has now run for 11 consecutive trading days. The cumulative loss over this period is 10%, trimming a portion of the stock’s longer-term gains for anyone holding the shares.
The company’s market capitalization now stands at about $15 billion after the persistent decline.
The Streak Next To The S&P 500
- A 5-Day Winning Streak Has CNH Industrial Stock Up 21%
- Figma Stock Slides 18% Over 5 Straight Down Days
- Cadence Design Systems Stock Slides 12% Over 5 Straight Down Days
- How Will Casey’s General Stores Stock React To Its Upcoming Earnings?
- HF Sinclair Stock Climbs 14% On A 7-Day Winning Streak
- Royal Caribbean Stock Slides 9.4% Over 8 Straight Down Days
Here is how BBIO stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | BBIO | S&P 500 |
|---|---|---|
| 1D | -1.4% | 1.1% |
| 11D (Current Streak) | -10.2% | 0.5% |
| 1M (21D) | -8.0% | 0.3% |
| 3M (63D) | 12.0% | 2.2% |
| YTD 2026 | -1.4% | 13.2% |
| 2025 | 178.8% | 16.4% |
| 2024 | -32.0% | 23.3% |
| 2023 | 429.8% | 24.2% |
Are the fundamentals justifying the recent pressure?
This move appears to be specific to the stock, as the S&P 500 returned +0.5% over the same 11 trading days. The market may be weighing a mixed fundamental picture. While revenue over the last twelve months grew 202.4%, far outpacing the S&P 500 median of 8.3%, profitability metrics show significant strain.
The company’s operating margin over the last twelve months is -67.0%, against a median of 18.6% for the index. BridgeBio Pharma also has negative trailing earnings, meaning it does not have a meaningful price-to-earnings multiple.
A streak is a signal, not a strategy.
A streak this long is information. It signals that the market’s attention is fixed on a stock, but it is not an instruction to act. The disciplined response is to check the business against the price.
The stock’s -8.0% return over the last month sits in contrast to its +45.5% gain over the trailing twelve months. A persistent move like this one is a prompt to re-evaluate, and the data on growth and profitability offers a place to begin that work.
If the drop has you weighing an entry, resist buying a falling price alone. Our Buy the Dip screen ranks the marked-down names where growth and cash generation still support a recovery.
And for anyone who would rather back the theme than one company’s story, a biotech ETF like XBI holds the sector rather than this one name. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
Weakness In One Name Should Be Noise, Not News
For a diversified holder, a streak like this is a data point. For a concentrated one, it is a hole in the plan. The difference is never the stock; it is the portfolio built around it.
Building that portfolio is what the Trefis High Quality (HQ) Portfolio does: roughly 30 businesses with the cash generation and balance-sheet strength to absorb a bad month, selected and rebalanced by rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Make the next streak, in either direction, someone else’s drama.